Pay in 4 interest-free payments of $5.45 Learn more
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4
Key benefits Why people compare it 1 40-60% greater healing outcomes versus either peptide alone 2 Simultaneous activation of early-phase (TB-500) and mid-phase (BPC-157) repair 3 Synergistic upregulation of both VEGF/EGF and actin-migration pathways 4 Dual anti-inflammatory action: NO system modulation plus cytokine reduction 5 Single-vial reconstitution eliminates dosing variability 6 Optimized 1:1 mass ratio matching published combination protocols 7 Thorough tendon, ligament, muscle, and joint repair support 8 No emergent toxicity beyond individual component profiles Deep research About BPC-157 / TB-500 Blend This blend combines two structurally and mechanistically distinct peptides: BPC-157 (a 15-amino acid pentadecapeptide, MW ~1419 Da, sequence GEPPPGKPADDAGLV) and TB-500 (a synthetic 43-amino acid replica of Thymosin Beta-4, MW ~4921 Da)
Its the gold standard for the pharmaceutical and compounding industry, ensuring strict regulatory oversight, especially for providers and clinical settings
These examples are supported by extensive clinical data and regulatory approval from Health Canada
Research-grade BPC-157 is sold as a laboratory chemical with no COA verification, frequently contains impurities, is often incorrectly dosed, and is not produced under any pharmaceutical quality standard
PMC PubMed Central
US$ 28.58
US$ 28.49
US$ 29.40
US$ 21.37
US$ 26.04
US$ 25.04
US$ 22.22
US$ 23.84